Insulet Corporation
Insulet Corporation (PODD) Stock Overview
Explore Insulet Corporation’s financial performance, market position, analyst ratings, and future outlook.
PODD Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Insulet Corporation (PODD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $223.30.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 53.88 and a market capitalization of 22B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Ms. Ashley A. McEvoy
3,900
100 Nagog Park, Acton, MA
2007